Pavella Therapeutics

Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel topical therapies for serious, rare genetic skin diseases and vascular malformations with no FDA-approved treatments. The company's proprietary QTORIN™ platform is designed to enable targeted, high-concentration topical drug delivery directly to affected skin tissues while minimizing systemic exposure. Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is currently under FDA rolling NDA review for the treatment of microcystic lymphatic malformations (mLM) and is in clinical development for cutaneous venous malformations (cVM) and clinically significant angiokeratomas. Additionally, the company is advancing QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis (DSAP).